
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
How can we streamline late-stage clinical development processes to speed regulatory submissions and approvals?-SAS Whitepaper






